Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel

Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1184
https://www.valueinhealthjournal.com/article/S1098-3015(15)03260-X/fulltext
Title : Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03260-X&doi=10.1016/j.jval.2015.09.1184
First page : A459
Section Title : Research Podium Presentations - Session 1 and Session 2
Open access? : No
Section Order : 683
Categories :
Tags :
Regions :
ViH Article Tags :